Pluristem Therapeutics, Inc (PSTI) is a regenerative medicine company focused on developing cell therapies for a range of diseases. The company's patented PLX (PLacental eXpanded) cell therapy products are derived from human placental cells, and are designed to release therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage.
PSTI's lead product candidate, PLX-PAD, is being developed to treat critical limb ischemia (CLI) and Buerger's disease. In addition to its CLI program, the company is also developing PLX-R18 for the treatment of acute radiation syndrome (ARS) and hematological indications, and PLX-Immune for the treatment of inflammatory and autoimmune diseases.
As of February 25th, 2023, PSTI had a market capitalization of approximately $228.4 million. It is a small-cap company listed on the NASDAQ exchange.
Pluristem Therapeutics, Inc (PSTI) is a regenerative medicine company focused on developing cell therapies for a range of diseases. The company's patented PLX (PLacental eXpanded) cell therapy products are derived from human placental cells, and are designed to release therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage.